U.S. court bars Martin Shkreli from pharma industry, orders $64.6 million payment By Reuters



© Reuters. FILE PHOTO: Former drug company executive Martin Shkreli exits U.S. District Court after being convicted of securities fraud, in the Brooklyn borough of New York City, U.S., August 4, 2017. REUTERS/Carlo Allegri

WASHINGTON (Reuters) – A U.S. court said on Friday that Martin Shkreli, who famously raised the price of Daraprim, would be ordered to pay $64.6 million and would be barred for life from the pharmaceutical industry.

The drug is used to treat toxoplasmosis, a parasitic infection that threatens people with weakened immune systems.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Source link

Hi!
It’s nice to meet you.

Sign up to receive awesome content in your inbox, every week.

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

Posting....
Exit mobile version